SCHEMBL5846711

SCHEMBL5846711

CC(C)=CCSc1ccc(Br)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.44
MAOA P21397 1/20 0.44
PPARD Q03181 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
HSP90AA1 P07900 1/20 0.37
KCNH2 Q12809 1/20 0.37
MAOB P27338 1/20 0.36
HPGD P15428 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
NFKB1 P19838 3/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CASP3 P42574 1/20 0.35
SENP8 Q96LD8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9189810 0.82 CA2 (0.41) MAOAKMT2AMEN1HSP90AA1KCNH2
SCHEMBL4313725 0.81 ALDH1A1 (0.48) MAOAMAOBHPGDNPC1RAB9A
SCHEMBL9856252 0.80 METAP2 (0.35) NFKB1POLBMAPTMETAP2TSHR
SCHEMBL4849060 0.79 MAOA (0.51) MAOAPPARDMAOBMAPTALDH1A1
SCHEMBL9856231 0.78 CA2 (0.44) SMN1; SMN2L3MBTL1KMT2AMEN1HPGD
SCHEMBL9856019 0.77 ALDH1A1 (0.35) MAOAMAOBNPC1RAB9ANFKB1
SCHEMBL6666656 0.77 PPARD (0.42) SMN1; SMN2PPARDL3MBTL1KMT2AMEN1
SCHEMBL6091563 0.76 METAP2 (0.33) MAOAPPARDMAOBNFKB1POLB
SCHEMBL21750687 0.73 GAA (0.61) SMN1; SMN2L3MBTL1KMT2AMEN1NPC1
SCHEMBL9190384 0.73 HSD17B10 (0.50) SMN1; SMN2KMT2AMEN1HSP90AA1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009116075-A2 PROCESS FOR PREPARATION OF TAZAROTENE INDOCO REMEDIES LIMITED (IN) 2009-09-24 WO disclosed
US-7148245-B2 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-12-12 US disclosed
WO-2006040644-A2 PROCESSES FOR THE PREPARATION OF SUBSTITUTED THIOCHROMAN DERIVATIVES RANBAXY LABORATORIES LIMITED (IN) 2006-04-20 WO disclosed
US-20040030141-A1 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them GALDERMA RESEARCH & DEVELOPMENT 2004-02-12 US disclosed
US-6649612-B1 Combating skin ageing and keratinization GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-11-18 US disclosed
EP-0952974-B1 BIPHENYL DERIVATIVES SUBSTITUTED BY AN AROMATIC OR HETEROAROMATIC RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME GALDERMA RES & DEV (FR) 2001-11-21 EP disclosed
US-6316009-B1 FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN GALDERMA RESEARCH & DEVELOPMENT (FR) 2001-11-13 US disclosed
EP-0879223-B1 AROMATIC POLYCYCLIC RETINOID-TYPE DERIVATIVES, METHOD FOR PREPARING SAME, AND USE THEREOF FOR MAKING PHARMACEUTICAL AND COSMETIC COMPOSITIONS CT EUROP DE BIOPROSPECTIVE CEB (FR) 2001-11-07 EP disclosed
CN-1285830-A Pyridylpyrrole derivatives SANKYO CO (JP) 2001-02-28 CN disclosed
EP-1031572-A1 PYRIDYLPYRROLE DERIVATIVES Sankyo Company Limited (JP) 2000-08-30 EP disclosed
US-5414007-A Skin disorders ALLERGAN, INC. (US) 1995-05-09 US disclosed
US-5349105-A Skin disorder ALLERGAN, INC. (US) 1994-09-20 US disclosed
US-5264456-A Skin disorders, anticarcinogenic agents, antiarthritic agents, immunology or wound healing agents ALLERGAN, INC. (US) 1993-11-23 US disclosed
US-5202471-A Skin disorders ALLERGAN, INC. (US) 1993-04-13 US disclosed
US-5175185-A Antiacne agents ALLERGAN, INC. (US) 1992-12-29 US disclosed
EP-0436398-A1 Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity ALLERGAN, INC. (US) 1991-07-10 EP disclosed
US-5015658-A Treatment of skin disorders such as psoriasis ALLERGAN, INC. (US) 1991-05-14 US disclosed
US-5013744-A Skin disorders ALLERGAN, INC. (US) 1991-05-07 US disclosed
EP-0405028-A1 Thiochroman esters of phenols and terephthalates having retinoid-like activity ALLERGAN, INC (US) 1991-01-02 EP disclosed
US-4895868-A PSORIASIS, SKIN DISORDERS, ANTIARTHRITIC, WOUND HEALING, EYE DRYNESS ALLERGAN, INC. (US) 1990-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040030141-A1 Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them AHR, TYR, CYP1A1 SMN1; SMN2 4680/4885MAOA 205/4885PPARD 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.